BLOCker sequencing
Transgenomics' CEO said these first forays into next-gen sequencing don't represent a shift in the company's strategy, which has so far been focused on Sanger sequencing and PCR technologies for molecular diagnostics.
Transgenomic Posts 22 Percent Decline in PGx Business, but Predicts Segment 'Swell' in Coming Months
Premium
A Transgenomic official said the company has signed deals "for a number of significant high-value projects" with pharmaceutical firms, which promise to "swell the [segment to] $1.5 million or more in the second quarter, plus [bring in] significant revenues throughout the remainder of the year."
The new method, called BLOCker sequencing, uses blocking oligos to increase the sensitivity of Sanger sequencing for specific mutations, for example in tumors or viral populations.